GSK shares slump as vaccine sales decline despite £8.9bn third-quarter revenue

GSK shares fell 5% despite £8.9bn Q3 revenue, up 5% YoY, as vaccine sales declined 2% to £2.6bn. Speciality medicines drove growth. Analysts remain divided on outlook. CEO Luke Miels highlighted strong quarterly performance and R&D focus.

Original reporting
Published Oct 28, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK shares slump as vaccine sales decline despite £8.9bn third-quarter revenue — source image
Decision brief

The 30-second read

$GSKBearishMed
01

Why it matters

The market reaction centers on the vaccine segment deterioration (Arexvy down 14%), which analysts interpret as a signal for tougher trading ahead, outweighing the headline revenue beat.

02

Market read

Traders can reassess near-term earnings quality and segment mix risk for GSK based on the disclosed vaccine revenue decline and product-level weakness.

03

What to watch

The piece mentions ongoing R&D acceleration and a Cambridge mega-campus funding plan, which could offset near-term vaccine softness if investors gain confidence in pipeline execution.

Relevance 7/10Novelty 6/10Timing: early trading Wednesday after Q3 revenue/vaccine segment disclosure

Background

GSK reported Q3 turnover of £8.9bn, up 5% YoY and 1% above analyst forecasts, but vaccine revenue fell 2% to £2.6bn.

Company-level read

Ticker impact

$GSKBearishHigh confidence
Context

GSK shares fell after the company reported a 2% decline in vaccine revenue to £2.6bn, with Arexvy down 14% in Q3.

Expected impact

Likely continued pressure as investors focus on the vaccine segment’s decline and potential for tougher trading in coming quarters.

Evidence & confidence

The article ties the early-trading drop directly to the vaccine revenue decline and cites management commentary plus analyst expectations of tougher quarters.

Market effects

Highlights sensitivity of large pharma valuations to vaccine demand trends, potentially affecting UK pharma sentiment broadly.

FTSE 100 pharma complex may see correlated selling if investors generalize vaccine weakness.

Global vaccine demand expectations could be repriced, though the article is primarily company-specific.

Counterpoint

Investors may be over-weighting the vaccine decline because the article notes speciality medicines are delivering double-digit growth and revenue still beat forecasts.

Key entities

  • GSK

    British pharmaceuticals company whose Q3 results and vaccine revenue decline drove the share selloff.

  • Luke Miels

    GSK CEO quoted emphasizing operational delivery, execution, and accelerating R&D.

  • Chris Beauchamp

    IG chief market analyst quoted warning that vaccine weakness points to tougher coming quarters.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.